Antibody responses to flagellin C and Streptococcus gallolyticus pilus proteins in colorectal cancer.
Adult
Aged
Aged, 80 and over
Antibodies, Bacterial
/ immunology
Case-Control Studies
Colorectal Neoplasms
/ complications
Female
Fimbriae Proteins
/ immunology
Fimbriae, Bacterial
/ immunology
Flagellin
/ immunology
Humans
Logistic Models
Male
Middle Aged
Spain
Streptococcal Infections
/ complications
Streptococcus gallolyticus
/ immunology
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
26 07 2019
26 07 2019
Historique:
received:
19
02
2019
accepted:
10
07
2019
entrez:
28
7
2019
pubmed:
28
7
2019
medline:
3
11
2020
Statut:
epublish
Résumé
Antibodies to Streptococcus gallolyticus subspecies gallolyticus (SGG) have been associated with colorectal cancer (CRC). Because SGG may correlate with impaired gut epithelia, we assessed the association of antibodies to bacterial flagellin C (FliC), a measure potentially related to this impairment, with CRC and the CRC-specific interaction with antibodies to SGG proteins. Antibodies to FliC and SGG pilus proteins Gallo2178 and Gallo2179 were measured in two independent studies, a combined study from Nijmegen and Detroit (93 CRC cases, 74 controls) and a replication data set including 576 cases and 576 controls from the Spanish multicenter multicase-control study (MCC-Spain). Logistic regression was applied to assess whether antibodies to FliC were associated with CRC and modified the association of antibodies to SGG proteins with CRC. Antibodies to FliC were associated with those to SGG Gallo2178 among CRC cases, resulting in an interaction in the association of antibodies to Gallo2178 with CRC (p = 0.007). This association was only present among individuals with high antibody responses to FliC (OR: 2.42, 95% CI: 1.45-4.06). In conclusion, our findings suggest that colorectal tumorigenesis could be accompanied by an impaired integrity of the epithelium that could result in associated increased antibody responses to bacterial proteins.
Identifiants
pubmed: 31350458
doi: 10.1038/s41598-019-47347-6
pii: 10.1038/s41598-019-47347-6
pmc: PMC6659640
doi:
Substances chimiques
Antibodies, Bacterial
0
Flagellin
12777-81-0
Fimbriae Proteins
147680-16-8
Types de publication
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
10847Subventions
Organisme : NCI NIH HHS
ID : R01 CA093817
Pays : United States
Références
Nutr Cancer. 2013;65(2):169-77
pubmed: 23441604
Int J Cancer. 2012 Nov 15;131(10):2294-9
pubmed: 22377818
Clin Chem. 2005 Oct;51(10):1845-53
pubmed: 16099939
Cancer. 2010 Sep 1;116(17):4014-22
pubmed: 20564125
J Natl Cancer Inst. 2013 Dec 18;105(24):1907-11
pubmed: 24316595
J Clin Invest. 2004 May;113(9):1296-306
pubmed: 15124021
Lancet. 2014 Apr 26;383(9927):1490-1502
pubmed: 24225001
Nat Rev Microbiol. 2012 Jun 25;10(8):575-82
pubmed: 22728587
Front Microbiol. 2018 Apr 03;9:614
pubmed: 29666615
PLoS Pathog. 2017 Jul 13;13(7):e1006440
pubmed: 28704539
Proc Natl Acad Sci U S A. 2018 Jan 9;115(2):E283-E291
pubmed: 29279402
Gac Sanit. 2015 Jul-Aug;29(4):308-15
pubmed: 25613680
Cancer Prev Res (Phila). 2012 Feb;5(2):260-5
pubmed: 22012878
J Infect Dis. 2011 Apr 15;203(8):1101-9
pubmed: 21451000
J Immunol. 2006 Sep 1;177(5):2810-8
pubmed: 16920916
BMC Cancer. 2013 Feb 26;13:91
pubmed: 23442743
BMC Cancer. 2009 Nov 19;9:403
pubmed: 19925668
Front Microbiol. 2018 Apr 10;9:603
pubmed: 29692760
Int J Cancer. 2018 Jul 15;143(2):245-252
pubmed: 29377173
Cancer Epidemiol Biomarkers Prev. 2016 Feb;25(2):291-301
pubmed: 26823475
Trends Microbiol. 2004 Nov;12(11):509-17
pubmed: 15488392
Sci Rep. 2018 Jan 24;8(1):1514
pubmed: 29367658
Int J Cancer. 2016 Apr 1;138(7):1670-9
pubmed: 26537841
J Infect Dis. 2011 Dec 15;204(12):1960-70
pubmed: 22043018
Int J Cancer. 2017 Sep 1;141(5):897-904
pubmed: 28477334